Exai Bio
formerly ExaiRNA & AI Liquid Biopsy for Early Cancer Detection
Palo Alto, United States · Founded 2021 · $67.5M raised
- Headquarters
- Palo Alto, California
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- exai.bio
- Total Funding
- $67.5M
- Last Round
- $67.5M Series ADec 2023
- Rounds
- 2
About
Exai Bio is an RNA-based liquid biopsy company using noncoding RNA and AI for early cancer detection from blood draws.
Summary
Exai Bio is an Artificial Intelligence company based in Palo Alto, United States, founded in 2021. It has raised $67.5M in total across 2 rounds, most recently a $67.5M Series A round in Dec 2023. Investors include Section 32, Casdin Capital and Two Sigma Ventures.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2023
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Next-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company